Supplementary Material

Table of Contents

Methods

Study participants

We studied participants in the EDSAB-HOME study (1), which recruited three key worker "streams". Two streams (Streams A, B) comprised Fire & Rescue or Police service key workers, or Health care key workers (n=1,139, n=1,533 respectively), independent of any history of COVID-19 disease or RT-PCR testing; for Stream C, a history of prior RT-PCR positive testing was required (n=154). The cohorts did not include acutely infected individuals; among the 268 (9.4%) cases who had had a prior positive RT-PCR result, the test had occurred a median of 63 days prior to recruitment. Recruitment occurred in June 2020. All participants provided written informed consent.

Individuals who were currently working at their place of work, or eligible to do so, aged 18 years or over, able to read English and to provide informed consent were eligible to enrol, as described [\(ISRCTN56609224\)](http://www.isrctn.com/ISRCTN56609224). Anyone currently experiencing COVID-19 compatible symptoms, who had experienced any in the last 7 days, meeting the UK Government's criteria for "exceptionally vulnerable", or taking part in any COVID-19 vaccine trials was ineligible.

Participants completed an online questionnaire prior to clinic attendance. On attending a study clinic, venous blood samples were taken from each participant. Each subject had a 6ml blood sample anticoagulated using EDTA, plasma was separated by centrifugation and stored at -80°C until use and 6ml (for the first 500 participants) or 10ml (thereafter) of blood anticoagulated with lithium heparin, stored at room temperature and shipped overnight to Oxford Immunotec (Milton Park, Oxon, UK) for T-SPOT® *Discovery* SARS-CoV-2 tests.

Laboratory Immunoassays

We characterised serological responses against SARS-CoV-2 using two commercial immunoassays: Roche Elecsys® anti-SARS-CoV-2 (2), and EUROIMMUN anti-S IgG immunoassays (1). We report the association between protection and the EUROIMMUN assay in this paper. Results failing immunoassays for technical reasons were repeated, as per normal clinical practice, and samples with insufficient volume for testing were excluded from analyses. We considered these assays positive if the Roche Elecsys® immunoassay signal was over 1.0, as recommended by the manufacturer, or the EUROIMMUN immunoassay index was over the 'confirmed' cutoff of 1.1 (1).

T-SPOT Discovery SARS-CoV-2 Testing

In brief, cells were purified from peripheral blood and SARS-CoV-2 responsive T cell numbers quantitated using a T-SPOT Discovery SARS-CoV-2 tests, which are based on the same proven analytical platform as the T-SPOT®.*TB* (tuberculosis) kit also produced by Oxford Immunotec.

In detail, peripheral blood mononuclear cells (PBMCs) were isolated from a whole blood sample using T-Cell *Select* reagent (Oxford Immunotec). The T-Cell *Select* kit contains a proprietary set of reagents consisting of buffer concentrate, antibodies, and superparamagnetic beads. Diluted T-Cell *Select* buffer is added to the whole blood sample to facilitate cell purification and reduce red blood cell contamination, and then antibodies are added which bind to the requisite immune cells in the sample. Cell separation was done using a validated automated platform, with a KingFisher magnetic separator (ThermoFisher). Cells were resuspended, counted using Guava flow cytometers (Luminex Corp), and following dilution 250,000 peripheral blood mononuclear cells per well were processed using T-SPOT *Discovery* SARS-CoV-2 tests, incubated for 16-20 hours at 37 degrees. Seven wells were used for each sample- 1. Nil Control to identify non-specific cell activation, Panels 2-6 SARS-CoV-2 specific antigen panels and Panel 7- Positive Control: Mitogen solution containing phytohaemagglutinin (PHA) to confirm PBMC functionality (Table S3). A second antibody, conjugated to alkaline phosphatase and directed to a different epitope on the cytokine molecule, is added and binds to the cytokine captured on the membrane surface. Any unbound conjugate is removed by washing. A soluble substrate is added to each well; this is cleaved by bound enzyme to form a spot of insoluble precipitate at the site of the reaction. Spots were read using automated cell counting equipment (CTL, Immunospot). The protocol followed the manufacturer's instructions exactly.

A sample was considered indeterminate if a) the Nil Control spot count was in excess of 6 spots per 250,000 PBMCs or b) the Positive Control well containing phytohemagglutinin (PHA) had less than 20 spots.

Masking

None of the individuals who ran the laboratory immunoassays, either serological or T-SPOT, had access to any information about the samples. The only exception is with the 154 Stream C samples. Stream C recruited after Streams A and B, and only contained PCR positive individuals. Laboratory staff knew this prior to sample receipt. All laboratory immunoassays were completed prior to any data analysis. Participants were made aware of their EUROIMMUN serological results approximately one month after their clinic visit, with a warning this was not indicative of protection from disease. Participants were not informed of their Roche or T-SPOT results. We derived the T-SPOT cutoff value, separating individuals with higher vs. lower SARS-CoV-2 responsive T cell numbers, based on separation of individuals with known SARS-CoV-2 infection vs. a low risk cohort; this activity preceded analysis of follow-up data.

Endpoints used on follow-up

The endpoint was having a SARS-CoV-2 RT-PCR positive test at least 12 days after recruitment.

For participants symptom driven testing was available without charge through state and employer routes. National criteria operate for obtaining such tests; these require at least one of a persistent cough, fever, or a change of taste or smell¹. Asymptomatic screening of contacts operated in some workplaces from 6 November 2020, in response to outbreaks. Nationally, SARS-CoV-2 RT-PCR test results are gathered by Public Health England (PHE)'s Second Generation Surveillance System (SGSS) with laboratory reporting by this route is required by law. Participants consented to national data systems being searched for their records.

Participants were matched using National Health Service (NHS) number (a unique identifier used by the NHS to identify all registered individuals). For 87% of participants, we were able to look up NHS numbers, which are not widely known by UK residents, by Demographics Batch Searches against NHS data systems. In all cases, we additionally performed searches based on surname, forename and data of birth to maximise ascertainment of SARS-CoV-2 RT-PCR results.

We performed additional checks on individuals with a positive endpoint as follows:

- 1. All positive results were reviewed manually and correct matching assured using geographic or and any other identifiers unused in the initial match.
- 2. Where available, the contemporaneous recorded symptom noted by the participant was checked. A proportion of volunteers agreed on recruitment to perform weekly symptom diaries. This was optional, and volunteers could opt out.

¹ [https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/get-a-test-to-check-if-you](https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/get-a-test-to-check-if-you-have-coronavirus/)[have-coronavirus/](https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/get-a-test-to-check-if-you-have-coronavirus/) accessed 10 October 2020

3. All participants with positive tests were sent an optional post-positive test questionnaire. This asked about symptoms and circumstances around the test.

For survival analysis, we started follow-up 12 days after the recruitment clinic visit, to avoid inclusion of individuals who may have been incubating infection at the clinic visit. This resulted in the exclusion of one individual only, who developed disease 5 days after recruitment. For the logistic regression analysis, we started follow-up on 8 July 2020, which is 12 days after the last participant was recruited.

Various national surveillance projects (such as those run by the Office for National Statistics², and the REACT1 study^{[3](#page-6-3)}), do offer tests to UK citizens. We excluded one individual with chronic post-COVID-19 symptoms who took such a test without any change in their symptoms. The individual was notified of the test result, which was positive, by the national surveillance project; the participant contacted the EDSAB-HOME study team to discuss this result as they (and we, subsequently) were unclear as to its interpretation. It may reflect a false positive test.

In late Sept-2020, a second wave of infection was beginning in England; for detail, see: <https://coronavirus.data.gov.uk/> and Figure S1.

Statistics

Objective 1: Describe baseline immunological responses to the SARS-CoV-2 virus

To explore and depict individuals' multi-dimensional immunological results (T-SPOT counts to six pools of peptides; immunoassay results), we performed hierarchical clustering, displaying results as heatmaps. In doing so, we transformed T-SPOT responses generating log_{10} (number of cells per 250,000 + 1), and transformed serological indexes (the raw value reported by the immunoassay) as log10 (immunoassay signal). This data was then clustered based on Minkowski distances using hierarchical clustering using Ward's method (4). Data were depicted using the R *hclust* function. In some analyses, we report the sum of T-SPOT responses to groups of wells, subtracting the background, see Supplementary Material Table S3. Comparing T-SPOT responses in two groups of

 $\overline{2}$

[https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinformation) [methodologies/covid19infectionsurveypilotmethodsandfurtherinformation](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinformation) accessed 10 Sept 2020 ³ <https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/> accessed 10 Sept 2020

individuals was done using Wilcoxon Ranked-sign tests, and more than two groups used Kruskal-Wallis tests.

To depict associations between immunological and clinical metadata (see Table S2), we computed Spearman correlation coefficients ρ, regarding ρ different from 0 if the associated *p* value was less than 0.01, adjusted for multiple comparisons using Bonferroni's method, depicting correlations as heatmaps.

To analyse the T-SPOT result of individuals, we computed the sum of T-SPOT responses to groups of panels, subtracting the background (Table S3). T-SPOT values optimally separating 154 individuals with high vs. 1087 individuals at low risk of past infection were computed (see Supp. Methods Fig. S6) using Youden's method (37). The high risk individuals had had previous positive RT-PCR tests. The low risk individuals reported no personal or household symptoms compatible with COVID-19 since January 2020, had had no positive RT-PCR tests, and had negative anti-Spike and anti-Nucleoprotein immunoassays using stringent cutoffs (index less than 0.35 for both assays).

Objective 2: Measure associations between baseline immunological responses and

subsequent COVID-19

To determine whether T-SPOT results or anti-Spike IgG concentrations (immunological predictors) were associated with protection from COVID-19, we started follow-up 12 days after the last recruitment (i.e. 8 July 2020), so subjects were followed for the same time. We did this to avoid inclusion of individuals who may have developed immune responses prior to symptom recognition, choosing the 12 day cutoff because only about 2.5% of cases have incubation periods longer than 11.5 days(38). Two endpoints were excluded on these grounds (see also Supplementary Materials).

We first quantified univariable associations between a number of baseline factors, including categorised antibody index (Table S4) and T-SPOT response. We similarly divided and analysed T-SPOT SNM responses. To quantify effect sizes, we used univariable and multivariable Poisson regression models including age (as a continuous variable), gender, high risk occupation (defined as being medical or nursing hospital staff), ethnicity (white vs. non-white) as well as (for time-to-event analyses) the average incidence (individuals testing positive in the last 7 days) in the NHS region of residence of the participant included as a time-dependent covariate. We also included T-SPOT

response and EuroImmun anti-Spike IgG assay result. In some analyses, we used categorisations of these (as above), and in others we modelled these as continuous variables. When modelling EuroImmun antibody indexes as continuous variables, we recoded values of over 10 as 10, as values over 10 indicate assay saturation. We then subtracted 0.35 from the variables, recoding negative values as zero, because we regard values less than 0.35 as representing technical assay background, with which disease risk is not expected to alter (see Results). We modelled square root transformed EuroImmun anti-Spike IgG index and square root transformed T-SPOT SNM responses, after selecting suitable transformations from linear, square root, log transform, 3 and 5 knot cubic splines using visual linearity and homoscedasticity assessment (by assessment of residuals), as well as Bayesian information criteria (BIC). In sensitivity analyses, we also used log transformations.

Analyses used R 4.0.2 or (for Poisson regression) Stata 16 for Windows.

Sample size calculations

Study size was aimed to achieve narrow confidence intervals around the performance of antibody detection tests, as described in the trial protocol (ISRCTN56609224).

References

1. Mulchandani R, Taylor-Phillips S, Jones H, Ades T, Borrow R, Linley E, et al. Self assessment overestimates historical COVID-19 disease relative to sensitive serological assays: cross sectional study in UK key workers. 2020:2020.08.19.20178186.

2. Evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunassays. Public Health England; 2020.

3. Hollander M, Wolfe D. Nonparametric statistical methods. New York: John Wiley & Sons; 1973. p. 185-94.
4. Everitt B

4. Everitt BS, Landau S, Leese M. Cluster Analysis: Wiley Publishing; 2009.

5. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine. 2020;26(6):845-8.

6. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. The New England journal of medicine. 2020.

7. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. 2020:2020.07.09.20148429. 8. Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of SARS-CoV-2 Antibody Avidity

Maturation and Association with Disease Severity. 2020:2020.07.30.20165522.

9. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. The Cochrane database of systematic reviews. 2020;6(6):Cd013652.

Tables

Table S1: Reported Seroconversion rates in acute SARS-CoV-2 infection

ND, not determined.

Table S2: EDSAB-HOME Demographics and exposure characteristics

*for only those who self-reported COVID-19 compatible symptoms. In addition, variables where the participant did not respond (NAs) amongst those who reported symptoms were not included (1 in Police and Fire and 3 in HCW). Final total was 939, split across Police and Fire (n=295), HCW (n=496) and HCW-PP (n=152).

Table S3: Peptide panel results reported

Details of the peptide panels in the T-SPOT *Discovery* SARS-CoV-2 test

Table S4: Categorisation of EuroImmun anti-Spike IgG index

Table S5: Responses to different peptide panels

Note: metric reported is

- 1. Observed cell number per 250,000 PBMC
- 2. (Panel1 + Panel $2 +$ Panel $3 +$ Panel $4) 4$ (Control), or zero is less than zero
- 3. (Panel $5 +$ Panel 6) 2(Control), or zero if less than zero

Table S6: Risk factors for high SNM T-SPOT results when seronegative

SNM T cell responses per 250,000 PBMC, measured by the T-SPOT® *Discovery* SARS-CoV-2 test in EDSAB-HOME participants, stratified by anti-Spike IgG serostatus as well as clinical and immunological features.

 $[LoW] weak (1.1 \sim in \text{idx} < 3) \tag{10} \tag{14} \tag{15} \tag{16} \tag{17} \text{Value}. \tag{19} \label{18} \text{Value}$
 $\text{Value:} \tag{19} \text{Value:} \tag{19} \text{Value:} \tag{19} \text{Value:} \tag{19} \text{Value:} \tag{19} \text{Value:} \text{Value:} \tag{19} \text{Value:} \text{Value:}$

Table S7: Continuous exposure variables: primary and sensitivity analyses

Poisson regression modelling of the relationship between outcome and immunological correlates of protection. Cell values are incidence rate ratios with 95% confidence intervals. There is statistical evidence from likelihood ratio tests that models including a T cell number and antibody signal interaction term improve model fit over predictions of a model including antibodies alone (cells marked *). Correlates of protection are modelled as log transformed variables.

Figures

Figure Legends

Figure S1: Outbreak in the UK and its relationship to follow-up

The outbreak kinetics in the UK, and its relationship to follow-up, are shown. Data is from coronavirus.data.go.uk.

Figure S2: Patterns of serological responses seen

The EuroImmun anti-Spike S1 IgG index is plotted against the Roche Nucleoprotein total antibody assay ratio. The manufacturer's recommended cutoffs are shown (1.0, 1.1 respectively), as is an exploratory cutoff for the EuroImmun assay (0.3, green line).

Figure S3: Correlations between responses to different SARS-CoV-2 components

Spearman correlation coefficients between the S1, S2, Nucleoprotein, Matrix protein, structural proteins and Envelope proteins, as well as anti-Nucleoprotein and S1 serological responses in 2,826 individuals from streams A,B and C.

Figure S4: SNM T-SPOT results compared with anti-Nucleoprotein antibody

SNM (Spike, Nucleoprotein and Matrix protein) responsive T cell numbers and their relationship to anti-Nucleoprotein serological responses in 2,672 from Streams A,B. (A) distribution of anti-N (Roche) serological assay index, and its relationship to symptoms. The vertical line is at 0.8, the manufacturer's 'borderline' cutoff. (B) bivariate plots of anti-N antibody responses and SNM T-SPOT results. The horizontal line corresponds to 12 spots / 250,000 cells. (C) distribution of SNM T-SPOT results. (D) As in B, but for Envelope and Structural proteins T-SPOT results; (E) distribution of Envelope and Structural (ES) T-SPOT results. In marginal histograms (A,C,E), the number of individuals reporting symptoms is depicted in red.

Figure S5: SNM responsive T cell numbers in individuals with previous positive PCR tests

SNM T-SPOT results and their relationship to anti-Spike S1 (EuroImmun) serological responses in 154 individuals with past SARS-CoV-2 infection from Stream C. (A) distribution of anti-Spike S1 (EuroImmun) serological assay index, and its relationship to symptoms. The vertical line is at 0.8, the manufacturer's 'borderline' cutoff. (B) bivariate plots of anti-S1 IgG responses and SNM T-SPOT results. The horizontal line corresponds to 12 spots / 250,000 cells. (C) distribution of SNM T-SPOT

results. (D) As in B, but for Envelope and Structural (ES) proteins T-SPOT results; (E) distribution of Envelope and Structural (ES) T-SPOT results. In marginal histograms (A,C,E), the number of individuals reporting symptoms is depicted in red.

Figure S6: Selection of cohorts at high and low risk of previous SARS-CoV-2 infection

Selection of high SARS-CoV-2 and low SARS-CoV-2 infection risk cohorts (A). (B) SNM T-SPOT results in these populations; (C) anti-S1 IgG responses in these populations; (D) bivariate plot showing anti-S1 IgG responses vs. SNM T-SPOT results. The blue box depicts individuals with elevated (more than 12 cells per 250,000 PBMC) responses who are seronegative.

Figure S7: ROC analysis separating low risk individuals from those with past infection

Receiver-operator curves showing separation of 1,126 individuals at low risk from historical SARS-CoV-2 infection from 154 individuals with proven infection by (A) SNM T-SPOT results; (B) Envelope and Structural protein (ES) T-SPOT results.

Fig. S3

Fire, Police and Healthcare worker staff reporting no COVID-19 related symptoms, no belief they had had COVID-19 nor any positive COVID-19 tests A

